5D is a triple-stage active antimalarial. It kills blood stages, liver stage, and mosquito stage malaria parasites. It has favorable pharmacokinetics, a simple synthesis process, is cost-effective, and is active against resistant strains of malaria.
From DBT India: Rs 9,800,000
Two patents: one US patent granted in 2022, and one India patent filed in 2020, currently under consideration. The technology is antimalarial.
Ramalingaswami Fellow - A.P. Singh
A highly competent team comprising Agam P. Singh, Brijesh Rathi, and Rajesh Anand.
Faculty
